Zhu Hui-Fang, Li Yan
State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, 132# Lanhei Road, Kunming, 650201, Yunnan, People's Republic of China.
University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of China.
Nat Prod Bioprospect. 2018 Aug;8(4):297-301. doi: 10.1007/s13659-018-0177-7. Epub 2018 Jul 5.
Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers. To date, over 50 phase III trials in cancer immunotherapy are in progress. Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention. The reported clinical success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation. But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and production cost. Therefore, alternative approaches including small-molecule-regulated immune response are being introduced. In this review, we focused on some of the key intracellular pathways where small-molecule therapeutic is potential and attractive, which highlights the great potential of natural products in this field.
癌症免疫疗法已被广泛认为是对抗癌症的一种有效方法。迄今为止，超过50项癌症免疫疗法的III期试验正在进行中。在众多免疫疗法中，免疫检查点疗法备受关注。报道显示，在癌症晚期通过抗体阻断靶向T细胞免疫检查点受体PD-1或CTLA4的临床成功证明了免疫调节的重要性。但基于抗体的免疫疗法存在一些缺点，如免疫原性、稳定性、膜通透性和生产成本等。因此，包括小分子调节免疫反应在内的替代方法正在被引入。在本综述中，我们重点关注了一些小分子治疗具有潜力且有吸引力的关键细胞内途径，这凸显了天然产物在该领域的巨大潜力。
